We are dedicated to advancing new therapies to improve the lives of people living with sickle cell disease and other hemoglobinopathies.
IMR-687 addresses both the white cell and red cell aspects of sickle cell pathology in a safe and easy to use oral pill. We are currently enrolling a phase 2a clinical trial with IMR-687 in adult patients with sickle cell disease.
Imara deeply cares about its patients, their care-givers, and the broader community affected by sickle cell disease. See our events section to find out more about sponsorship and participation in sickle cell related events.
Imara Inc., is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies.